NCT04678739View on ClinicalTrials.gov

Efficacy and Safety of Remdesivir and Tociluzumab for the Management of Severe COVID-19: A Randomized Controlled Trial

PHASE3CompletedINTERVENTIONAL

Enrollment

205

Participants

Timeline

Start Date

August 15, 2020

Primary Completion Date

January 30, 2021

Study Completion Date

February 10, 2021

Conditions

Covid19Covid-19 ARDS

Interventions

DRUG

Remdesivir

Remdesivir 100 IV Infusion as a lyophilized powder

DRUG

Tocilizumab

Actemra IV Infusion

Trial Locations (4)

4000

Chattogram General Hospital, Chittagong

5200

M. Abdur Rahim Medical College Hospital, Dinajpur

Unknown

Cox's Bazar 250 Bed District Sadar Hospital, Cox’s Bāzār

M. Abdur Rahim Medical College Hospital, Dinajpur

All Listed Sponsors

lead

M Abdur Rahim Medical College and Hospital

OTHER_GOV

collaborator

First Affiliated Hospital Xi'an Jiaotong University

OTHER

collaborator

Cox's Bazar 250 Bed District Sadar Hospital

UNKNOWN

collaborator

Chattogram General Hospital

OTHER_GOV

NCT04678739 - Efficacy and Safety of Remdesivir and Tociluzumab for the Management of Severe COVID-19: A Randomized Controlled Trial | Biotech Hunter | Biotech Hunter